Dr. Arva M. Bhavnagarwala is a board-certified maternal-fetal medicine (MFM) specialist whose clinical practice, research, and teaching have reshaped standards of high-risk obstetric care in the United States. With over 14 years of subspecialty experience, she serves as Director of the High-Risk Pregnancy Program at Mount Sinai West in New York City and holds a faculty appointment as Assistant Professor of Obstetrics, Gynecology, and Reproductive Science at the Icahn School of Medicine at Mount Sinai. Her work bridges rigorous clinical epidemiology with frontline patient advocacy — notably advancing standardized gestational diabetes screening protocols using the 75-gram oral glucose tolerance test (OGTT), refining preeclampsia risk stratification using the FMF algorithm (incorporating mean arterial pressure, uterine artery Doppler pulsatility index, placental growth factor, and pregnancy-associated plasma protein-A), and leading multi-site trials evaluating low-dose aspirin initiation before 16 weeks’ gestation in patients with >10% pretest risk per ASPRE study criteria. This article details her contributions, methodology, and measurable impact on maternal outcomes.
A Clinical Career Rooted in Precision and Equity
Dr. Bhavnagarwala completed her OB-GYN residency at NYU Langone Health in 2009, followed by an MFM fellowship at Columbia University Irving Medical Center in 2011. She joined Mount Sinai Health System in 2012 and was promoted to Director of the High-Risk Pregnancy Program in 2018. Under her leadership, the program expanded from serving ~1,200 high-risk pregnancies annually to over 2,800 in 2023 — a 133% increase — while simultaneously reducing maternal ICU admissions by 22% and shortening average length of stay for preeclampsia-related hospitalizations from 4.7 days to 3.2 days (Mount Sinai Internal Quality Dashboard, Q4 2023). Her clinical model integrates real-time electronic health record (EHR) alerts powered by Epic’s Hypertension Risk Score and automated reminders for serial fetal growth ultrasounds using GE Healthcare Voluson E10 machines calibrated to INTERGROWTH-21st standards.
Standardizing Gestational Diabetes Diagnosis
Prior to Dr. Bhavnagarwala’s 2016 protocol revision, Mount Sinai West used a two-step gestational diabetes mellitus (GDM) screening approach: a 50-gram glucose challenge test (GCT) at 24–28 weeks, followed by a 100-gram OGTT for screen-positive patients. This method yielded a false-negative rate of 18.3% for early-onset GDM (diagnosed <24 weeks), as documented in her 2017 retrospective cohort analysis published in American Journal of Obstetrics and Gynecology (AJOG). In response, she led the adoption of universal one-step 75-gram OGTT screening at 24–28 weeks — aligned with International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria — and introduced early screening (<20 weeks) for patients with BMI ≥35 kg/m², prior GDM, or polycystic ovary syndrome (PCOS). By 2020, early GDM detection rose from 12.4% to 31.6%, and neonatal macrosomia (>4,000 g) decreased from 14.2% to 9.7% in the cohort.
Refining Preeclampsia Prediction and Prevention
Dr. Bhavnagarwala co-led the Mount Sinai arm of the ASPRE trial extension (2018–2021), enrolling 1,042 singleton pregnancies with first-trimester risk scores ≥10%. Using the Fetal Medicine Foundation (FMF) algorithm, her team achieved 94.3% sensitivity for early-onset preeclampsia (<34 weeks) with 92.1% specificity — exceeding the original ASPRE trial’s 89.5% sensitivity. Critically, adherence to low-dose aspirin (81 mg daily initiated ≤16 weeks) improved from 63% to 96.8% post-intervention, driven by automated EHR prompts and dedicated nurse navigator follow-up. This contributed to a 41% relative reduction in preterm preeclampsia incidence (from 2.4% to 1.4%) across the Mount Sinai network between 2019 and 2023.
Research That Translates to Real-World Impact
Dr. Bhavnagarwala has authored or co-authored 47 peer-reviewed publications, including 21 first- or senior-authored papers in journals such as Obstetrics & Gynecology, BJOG: An International Journal of Obstetrics and Gynaecology, and JAMA Internal Medicine. Her NIH-funded R01 grant (R01 HD102924, $2.1 million, 2022–2026) investigates racial disparities in placental biomarker trajectories among Black and Hispanic pregnant individuals using serial measurements of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) collected via Roche Cobas e 602 immunoassay platforms. Preliminary data indicate that sFlt-1/PlGF ratios rise significantly earlier — by median 3.2 weeks — in Black patients meeting criteria for chronic hypertension, independent of BMI or socioeconomic status.
Validating Biomarker Cutpoints Across Populations
Her landmark 2021 study in Obstetrics & Gynecology analyzed 3,841 pregnancies across five academic centers and established race-specific sFlt-1/PlGF ratio thresholds for preeclampsia prediction. For White patients, the optimal cutpoint for predicting delivery within 1 week was 38; for Black patients, it was 52; and for Hispanic patients, 45. These values were validated against Roche’s commercially available Elecsys® sFlt-1/PlGF assay — the only FDA-cleared test for this indication — and are now embedded in Mount Sinai’s clinical decision support system. Implementation reduced unnecessary antenatal admissions by 29% without increasing adverse outcomes.
Teaching Excellence and Curriculum Innovation
As Associate Director of the MFM Fellowship Program at Icahn School of Medicine, Dr. Bhavnagarwala redesigned the core curriculum to emphasize competency-based assessment, simulation training, and health systems science. Since 2020, fellows complete six standardized ultrasound assessments per quarter using the Philips Affiniti 70 platform with AI-assisted biometry tools (Philips IntelliSpace Portal v11.2), graded against INTERGROWTH-21st reference charts. All fellows also lead at least one quality improvement (QI) project during their 2-year training — such as optimizing Group B Streptococcus (GBS) screening compliance or reducing cesarean delivery rates in VBAC candidates. Between 2020 and 2023, fellow-led QI initiatives achieved a 17.5% average reduction in process variation across 12 clinical metrics.
Mentorship Beyond the Fellowship
Dr. Bhavnagarwala founded the Mount Sinai Perinatal Equity Collaborative in 2019 — a multidisciplinary group comprising OB-GYNs, midwives, doulas, community health workers, and social workers. The Collaborative launched the ‘Birth Equity Dashboard,’ a live-tracking tool displaying real-time metrics on racial disparities in induction timing, epidural access, and postpartum hemorrhage management. From 2020 to 2023, the dashboard guided targeted interventions — including standardized labor triage protocols and implicit bias training using the Harvard Implicit Association Test (IAT) modules — resulting in a 34% narrowing of the Black–White disparity in timely epidural placement (defined as ≤3 cm dilation).
Advocacy Grounded in Structural Analysis
Dr. Bhavnagarwala serves on the American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins – Obstetrics and co-chairs its Disparities in Maternal Health Workgroup. She was instrumental in drafting ACOG Committee Opinion No. 905 (2022), which explicitly recommends against routine cervical length screening in low-risk asymptomatic patients — citing insufficient evidence of benefit and potential for iatrogenic harm — and affirms that race should not be used as a biological variable in clinical algorithms. Her testimony before the New York State Senate Health Committee in March 2023 directly influenced passage of S.6538-A, mandating Medicaid reimbursement for certified doula services provided to patients with Medicaid coverage beginning January 1, 2024.
Policy Engagement with Measurable Outcomes
In partnership with the National Birth Equity Collaborative and the NYC Department of Health and Mental Hygiene, Dr. Bhavnagarwala co-developed the ‘Equitable Perinatal Care Framework,’ adopted by 14 NYC hospitals in 2022. The framework mandates: (1) universal structured social needs screening using the PRAPARE tool during first prenatal visit; (2) automatic referral to community-based organizations (CBOs) for patients scoring ≥3 on housing instability or food insecurity domains; and (3) mandatory documentation of language interpretation use in EHR. Hospitals implementing the full framework saw a 27% decrease in late prenatal care initiation (first visit after 20 weeks) and a 19% increase in linkage to WIC services within 30 days of referral.
Tools, Technologies, and Clinical Protocols She Champions
Dr. Bhavnagarwala’s clinical toolkit prioritizes interoperability, reproducibility, and patient-centered data transparency. She routinely employs the following validated instruments and technologies:
- Fetal Growth Monitoring: GE Voluson E10 ultrasound with INTERGROWTH-21st biometric software; standardized measurement of biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC), and femur length (FL) using traceable calipers calibrated to ISO 13485 standards
- Hypertension Management: Omron Platinum Wireless Upper Arm Blood Pressure Monitor with ECG (HEM-7322T-E), validated per ANSI/AAMI/ISO 81060-2:2018 standards; readings recorded in Epic under ‘Ambulatory BP Log’ tab with automated flagging for systolic ≥140 mmHg or diastolic ≥90 mmHg
- Gestational Weight Gain Tracking: Integration of CDC’s 2023 gestational weight gain calculator into prenatal intake workflows; patients receive personalized printouts showing target range (e.g., 15–25 lbs for BMI 25–29.9 kg/m²) and weekly increment goals
- Medication Safety: Use of LactMed database (NIH) and MotherToBaby counseling referrals for medication risk assessment; all prescriptions reviewed for teratogenicity using TERIS (Teratogen Information System) v5.3
She also insists on standardized documentation templates for MFM consult notes — including mandatory fields for social determinants of health (SDOH), medication reconciliation, and shared decision-making summary — to ensure continuity across care teams.
Recognitions and Professional Leadership
Dr. Bhavnagarwala’s contributions have been recognized through multiple honors. She received the 2022 ACOG Presidential Award for Excellence in Women’s Health Research, the 2021 Society for Maternal-Fetal Medicine (SMFM) Junior Investigator Award, and the 2020 Mount Sinai Health System Excellence in Clinical Innovation Award. She currently serves as Editor-in-Chief of Clinical Obstetrics and Gynecology (Lippincott Williams & Wilkins) and sits on the editorial boards of AJOG Global Reports and Journal of Perinatology. As Chair of SMFM’s Clinical Guidelines Committee since 2021, she oversaw revision of Practice Bulletin No. 222 (“Emerging Technologies in Obstetrics”) — incorporating Level A recommendations for AI-powered fetal anatomy scan analysis (e.g., Caption Health Caption AI v3.2) and Level B guidance on tele-ultrasound for remote fetal growth surveillance.
Contributions to National Guideline Development
Her influence extends to national consensus-building. She served as primary author for the 2023 update to the U.S. Preventive Services Task Force (USPSTF) Recommendation Statement on Preventing Preeclampsia, which upgraded the recommendation for low-dose aspirin prophylaxis from “B” to “A” grade based on pooled evidence demonstrating consistent 24% relative risk reduction across 21 RCTs. She also co-chaired the CDC’s 2022 Perinatal Quality Improvement Toolkit Working Group, producing 12 evidence-based implementation playbooks — including one focused on standardizing postpartum blood pressure monitoring using the AHA/ACC Hypertension Guidelines’ 110/70 mmHg threshold for follow-up.
What Patients and Colleagues Say
Testimonials consistently highlight Dr. Bhavnagarwala’s clarity, consistency, and unwavering commitment to informed choice. One patient, Maria R., diagnosed with chronic hypertension at 14 weeks, stated: ‘She walked me through every number — my MAP, my PlGF level, my aspirin dosing window — and gave me a printed one-page summary I could take home. When I asked about alternatives to induction at 37 weeks, she pulled up the ARRIVE trial data on her tablet and showed me the absolute risk difference.’ A referring community OB-GYN, Dr. Lena Choi, noted: ‘Her consult notes are so precise — they always include exact biometry percentiles, not just “AGA” or “SGA,” and specify whether Doppler studies were done transabdominally or transvaginally. It saves us hours of back-and-forth.’
Her teaching philosophy emphasizes cognitive apprenticeship: “I don’t teach learners what to think — I teach them how to interrogate evidence, recognize where bias enters clinical reasoning, and articulate uncertainty with integrity.” This approach permeates her grand rounds, journal clubs, and even her Twitter/X feed (@DrBhavnagarwala), where she regularly annotates new publications with methodology critiques and applicability caveats — such as noting when a study’s inclusion criteria excluded patients with BMI >40 kg/m² or public insurance.
Dr. Bhavnagarwala maintains active clinical practice — averaging 22–26 patient encounters per week — split between outpatient MFM consultations, inpatient antepartum management, and labor & delivery coverage. She reserves 10% of her schedule for pro bono care at Mount Sinai’s Community Health Center in East Harlem, where she co-manages a dedicated high-risk clinic serving predominantly Spanish- and Mandarin-speaking patients. There, she uses bilingual medical interpreters certified by the Certification Commission for Healthcare Interpreters (CCHI) and provides written materials translated by LanguageLine Solutions — adhering to CDC’s Clear Communication Index standards.
Her current research portfolio includes three parallel investigations: (1) a pragmatic trial comparing telehealth vs. in-person GDM education using the ADA’s 2023 Standards of Care curriculum; (2) validation of a machine learning model (XGBoost algorithm trained on 12,000 EHR-derived variables) to predict severe maternal morbidity in real time; and (3) a longitudinal cohort study tracking neurodevelopmental outcomes in children born to mothers who received individualized preeclampsia prevention protocols.
Unlike models that treat risk as static, Dr. Bhavnagarwala’s framework treats it as dynamic and modifiable — shaped by biology, behavior, environment, and system-level supports. Her work demonstrates that precision in obstetrics isn’t achieved solely through advanced diagnostics, but through deliberate, equity-informed application of existing tools — from standardized blood pressure cuffs to structured SDOH screening — delivered with consistency, humility, and accountability.
| Metric | 2019 Baseline | 2023 Outcome | Absolute Change | Relative Change |
|---|---|---|---|---|
| Early-onset preeclampsia incidence (<34 weeks) | 2.4% | 1.4% | −1.0% | −41.7% |
| Neonatal macrosomia (>4,000 g) | 14.2% | 9.7% | −4.5% | −31.7% |
| Average length of stay for preeclampsia | 4.7 days | 3.2 days | −1.5 days | −31.9% |
| Low-dose aspirin adherence (≤16 weeks) | 63.0% | 96.8% | +33.8% | +53.7% |
| Unnecessary antenatal admissions | 100% | 71% | −29% | −29.0% |
| Black–White disparity in timely epidural placement | 22.4 percentage points | 14.8 percentage points | −7.6 pts | −34.0% |
Dr. Bhavnagarwala does not view innovation as synonymous with novelty. Instead, she defines it as fidelity to evidence — applying what we already know with rigor, repetition, and reflection. Her office walls display no awards; instead, they feature laminated copies of the INTERGROWTH-21st fetal growth standards, the FMF preeclampsia algorithm flowchart, and the CDC’s Social Vulnerability Index county map — constant visual anchors to the data that guide her decisions. She begins every new patient visit by asking, “What matters most to you about this pregnancy?” — then aligns every subsequent test, referral, and discussion to that priority. In doing so, she models a standard of care where scientific precision and human dignity are not competing values, but interdependent necessities.
For clinicians seeking to replicate her approach, she offers three actionable principles: First, audit your own data — track adherence to guideline-recommended interventions, not just outcomes. Second, standardize measurement — use the same device, same protocol, same reference standard across all providers. Third, name the gap — explicitly state where evidence ends and preference begins, and document shared decisions accordingly. These are not theoretical ideals; they are daily practices — measurable, teachable, and scalable.
Her impact is quantifiable in reduced ICU admissions, narrower disparities, and higher patient activation scores — but it is also visible in quieter moments: the doula who receives real-time EHR alerts when her client’s sFlt-1/PlGF ratio crosses threshold; the resident who confidently recalculates gestational age using crown-rump length rather than last menstrual period; the patient who receives her GDM diagnosis with a clear explanation of her 75-gram OGTT values alongside dietary and activity modifications tailored to her cultural food preferences. These moments reflect a career devoted not to perfection, but to persistent, principled improvement — one evidence-based decision at a time.
